Richard H. Fearon
Richard H. Fearon's purchase track record
How the stock did after each of Richard H. Fearon's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2026 | CRH | $397K | -3.5% | -13.8% | +12.7% |
| 3/6/2026 | WAT | $306K | +20.8% | +35.3% | +14.5% |
| 5/28/2024 | WAT | $333K | +1.5% | +17.0% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Crown Holdings Price Target to $116. UBS has lowered its price target for Crown Holdings to $116 while maintaining a Neutral rating. This new target is below the current support level of $118.66, suggesting potential downside pressure. The move stands out as the new target is significantly lower than the average analyst estimate of $136.57.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CRH Confirms Q3 2026 Results Date Amid Supply Disruptions. CRH has confirmed the date for its Q3 2026 earnings release, a standard corporate update that anchors the company's upcoming financial reporting schedule. Recent market commentary notes that disrupted supply chains and tighter policy environments have created volatility in resource markets, which may influence how investors interpret these upcoming results. The stock has shown mixed performance recently, with some periods of decline relative to the broader market, while others saw gains during general market dips.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Waters Launches AI Link for LC-MS Workflows. Waters Corporation introduced AI Link, a tool designed to advance AI-enabled LC-MS workflows from research to release. This product launch highlights the company's focus on integrating artificial intelligence into its laboratory solutions. Additionally, TD Cowen raised its price target to $515, reflecting continued analyst interest in the stock's potential.
Transaction History
| AVNT | ▲ Buy | Grant | 958 | $0 | 9/30/2026 | View on chart |
| CCK | ▲ Buy | Grant | 351 | $41K | 7/29/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,049 | $0 | 6/30/2026 | View on chart |
| CRH | ▲ Buy | Option Exercise | 2,004 | $0 | 5/13/2026 | View on chart |
| CRH | ▼ Sell | Tax Withholding | 962 | $105K | 5/13/2026 | View on chart |
| CCK | ▲ Buy | Grant | 417 | $41K | 5/6/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,072 | $0 | 3/31/2026 | View on chart |
| CRH | ▲ Buy | Open Market | 3,800 | $397K | 3/11/2026 | View on chart |
| WAT | ▲ Buy | Open Market | 1,000 | $306K | 3/6/2026 | View on chart |
| WAT | ▲ Buy | Grant | 23 | $0 | 2/25/2026 | View on chart |
| CCK | ▲ Buy | Grant | 371 | $41K | 2/13/2026 | View on chart |
| WAT | ▲ Buy | Grant | 307 | $0 | 1/2/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,239 | $0 | 12/31/2025 | View on chart |
| CCK | ▲ Buy | Grant | 406 | $40K | 10/29/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,192 | $0 | 9/30/2025 | View on chart |
| CCK | ▲ Buy | Grant | 389 | $40K | 7/30/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,187 | $0 | 6/30/2025 | View on chart |
| CCK | ▲ Buy | Grant | 414 | $40K | 5/7/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,055 | $0 | 3/31/2025 | View on chart |
| CCK | ▲ Buy | Grant | 454 | $40K | 2/14/2025 | View on chart |
| WAT | ▲ Buy | Grant | 319 | $0 | 1/2/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 955 | $0 | 12/31/2024 | View on chart |
| CCK | ▲ Buy | Grant | 420 | $40K | 10/28/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 775 | $0 | 9/30/2024 | View on chart |
| CCK | ▲ Buy | Grant | 466 | $40K | 7/31/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 806 | $0 | 6/28/2024 | View on chart |
| WAT | ▲ Buy | Open Market | 1,000 | $333K | 5/28/2024 | View on chart |
| CCK | ▲ Buy | Grant | 482 | $40K | 5/8/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 808 | $0 | 3/29/2024 | View on chart |
| CCK | ▲ Buy | Grant | 536 | $40K | 2/14/2024 | View on chart |
| WAT | ▲ Buy | Grant | 334 | $0 | 1/2/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 1,040 | $0 | 12/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 834 | $0 | 12/29/2023 | View on chart |
| CCK | ▲ Buy | Grant | 499 | $40K | 11/1/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 984 | $0 | 9/29/2023 | View on chart |
| CCK | ▲ Buy | Grant | 428 | $40K | 8/2/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 863 | $0 | 6/30/2023 | View on chart |
| CCK | ▲ Buy | Grant | 475 | $40K | 5/3/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 857 | $0 | 3/31/2023 | View on chart |
| WAT | ▲ Buy | Grant | 302 | $91K | 3/27/2023 | View on chart |
| CCK | ▲ Buy | Grant | 465 | $40K | 2/16/2023 | View on chart |
| CCK | ▲ Buy | Grant | 583 | $40K | 11/2/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| CCK | ▲ Buy | Grant | 413 | $40K | 7/29/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 880 | $0 | 6/30/2022 | View on chart |
| CCK | ▲ Buy | Grant | 363 | $40K | 5/4/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 717 | $0 | 3/31/2022 | View on chart |
| CCK | ▲ Buy | Grant | 336 | $40K | 2/17/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 627 | $0 | 12/31/2021 | View on chart |
| CCK | ▲ Buy | Grant | 348 | $36K | 11/3/2021 | View on chart |
| AVNT | ▲ Buy | Grant | 744 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.